Former Senator Ben Sasse Discusses Experimental Cancer Treatment

Several months after announcing his stage 4 cancer diagnosis, former U.S. Senator Ben Sasse is opening up about a new treatment option that he hopes could prolong his life.

Sasse, a Republican who served Nebraska from 2015 until 2023, disclosed his battle with metastatic pancreatic cancer in December 2025. His condition involved cancer cells spreading to various organs, including the liver and lungs.

After being given just a few months to live initially, Sasse, age 54, joined a clinical trial for a drug named Daraxone Lasib. This oral medication aims to block a faulty gene responsible for unregulated cell growth.

Revolution Medicines, a pharmaceutical company based in California, recently published findings from a Phase 3 trial involving patients with metastatic pancreatic cancer who had not responded to standard chemotherapy. Interestingly, patients who received the new treatment had a median survival of 13 months, compared to approximately 6 months for those continuing with chemotherapy.

Sasse reported a significant reduction in pain since his diagnosis, stating that his tumor volume has decreased by 76 percent over the past four months during an interview with “60 Minutes.”

Dr. Sarvajit Mukherjee, who specializes in gastrointestinal medical oncology, explained how Daraxone Lasib works by targeting a crucial growth switch, known as RAS, that is often stuck in the “on” position in most pancreatic cancer cases—continuously signaling cancer cells to grow and multiply.

“This drug is designed to attach to active RAS and inhibit its signals, potentially slowing cancer progression,” a doctor who did not participate in the trial noted.

In the words of Dr. Mukherjee, the improvements in survival rates observed during the trial represent a substantial leap forward for a type of cancer that usually has a much shorter prognosis. He called the drug “the first targeted therapy for pancreatic cancer” and expressed hope that its developments could lead to more personalized treatment options in the future.

Diagnosing pancreatic cancer early is notoriously difficult, often due to the lack of symptoms or only mild gastrointestinal issues until the disease has spread significantly. The reality is that current chemotherapy treatments can indeed shrink tumors and extend life, but they come with demanding side effects. When traditional treatments fail, options typically diminish significantly, leaving survival as a matter of months.

Early evidence suggests that combining Daraxone Lasib with standard chemotherapy may improve outcomes even further, contributing to more significant tumor shrinkage.

If approved, the drug could serve as a valuable option for patients when other treatments become ineffective. However, Mukherjee cautions that while the drug is generally well-tolerated compared to traditional chemotherapy, it does have side effects. Common symptoms include rashes, diarrhea, mouth sores, and fatigue, necessitating regular blood tests and consistent follow-up.

As Sasse navigates this challenging journey, he credits both his faith and the exploratory drug for what he describes as a miraculous turn of events. He humorously reflects on receiving a terminal diagnosis in his early 50s, noting how people suddenly treat him as if he possesses the wisdom of a much older person.

“I don’t know about having a lot of wisdom, but I believe there are many concepts worth exploring together,” he shared.